What is HC Wainwright’s Forecast for ACHV FY2028 Earnings?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Research analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for Achieve Life Sciences in a report issued on Tuesday, May 12th. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will post earnings of $0.24 per share for the year, down from their prior forecast of $0.36. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.34) per share.

Several other equities analysts have also weighed in on ACHV. Weiss Ratings lowered shares of Achieve Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Canaccord Genuity Group set a $13.00 price target on shares of Achieve Life Sciences and gave the stock a “buy” rating in a research note on Monday, April 20th. Finally, Wall Street Zen upgraded shares of Achieve Life Sciences from a “strong sell” rating to a “sell” rating in a report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $14.67.

Achieve Life Sciences Trading Up 7.2%

Shares of NASDAQ ACHV opened at $5.99 on Wednesday. The business has a 50 day simple moving average of $4.00 and a 200 day simple moving average of $4.45. Achieve Life Sciences has a 52 week low of $2.00 and a 52 week high of $6.15. The stock has a market cap of $318.85 million, a price-to-earnings ratio of -4.61 and a beta of 2.25. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.39 and a current ratio of 4.39.

Achieve Life Sciences (NASDAQ:ACHV) last posted its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.11.

Institutional Investors Weigh In On Achieve Life Sciences

A number of large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC acquired a new position in Achieve Life Sciences during the first quarter valued at approximately $32,000. Next Capital Management LLC acquired a new stake in shares of Achieve Life Sciences in the third quarter worth $51,000. Sender Co & Partners Inc. acquired a new stake in shares of Achieve Life Sciences in the second quarter worth $56,000. OneDigital Investment Advisors LLC bought a new stake in shares of Achieve Life Sciences during the 3rd quarter worth $63,000. Finally, Magnolia Capital Advisors LLC bought a new stake in shares of Achieve Life Sciences during the 4th quarter worth $64,000. Institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.